DUE DILIGENCE FOR
VC & INVESTORS

Are you about to invest in a company claiming to have a NEW DRUG CANDIDATE for Glaucoma or AMD?

373-hd-loop-min.gif

Pharmaceutical development is beset with problems which are well understood.

Only 1 in 5000 molecules make it into clinical programmes.
Only 12% of new drug candidates make it through clinical trials, with only 20% of these achieving a successful ROI.
The average time to market for a new drug candidate is 12 years. 

De-risk your investment with DARC.

 

HOW CAN DARC HELP YOU?

 
 
VC-2-_-TEST.png

DARC DE-RISKS YOUR INVESTMENT

Find out if the new drug candidate works within weeks.

Use DARC to triage patients, de-risking clinical trial outcomes.

Identify non-effective drug candidates within weeks instead of months/years.

Increase your ROI by de-risking with DARC.

 

Before you invest in a new drug candidate, invest in DARC.